1. Provides written informed consent approved by an Independent Ethics Committee (IEC)
prior to any study related activities
2. Healthy male or female volunteers between 18 and 65 years of age (both inclusive)
3. Body mass index (BMI) between 19 and 30 kg/m^2, inclusive, and body weight of not kg or >100 kg
4. Non-smoker (defined as a subject who has not smoked and has not used nicotine
containing products for at least 3 months prior to study drug administration and has a
negative urine screen for cotinine) at Screening
5. Female subjects of childbearing potential and male subjects and their partners of
childbearing potential, agree to pregnancy prevention throughout the duration of the
study (through the Follow-up Visit). Subjects and their partners must agree to use of
an effective method of contraception, to avoid impregnation of females throughout the
course of the study.
Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior
to Screening. Adequate forms of contraception to be used include hormonal contraceptives
(oral, patch, depot), intrauterine devices (IUD), barrier contraceptive methods, such as
diaphragm, cervical cap/shield, male condoms and female condoms.Sexually active subjects
must use contraception while on study drug from admission to the Follow-up Visit. Male
subjects must also refrain from donating sperm from admission to the Follow-up visit 6.
Willing and able to comply with the requirements of the protocol and available for the
planned duration of the study
1. Any active systemic or immunologic disease or condition, including but not limited to
the following general categories: cardiovascular/pulmonary, hepatorenal, or systemic
infection, or lactation
2. History of, or current, malignancy with the exception of adequately treated squamous
or basal cell carcinoma of the skin or cervical carcinoma in situ within 5 years
3. Any disease or condition that might interfere with the absorption, distribution,
metabolism, or excretion of the study drug or would place the subject at increased
risk
4. Hematologic laboratory abnormalities including leukocytosis (defined as total
leukocytes >11,000/?L), leukopenia (defined as total leukocytes (defined as ANC
5. Clinically significant, as judged by the investigator, vital sign or 12-lead ECG
abnormality
6. History of biological growth factor exposure, including but not limited to filgrastim
and other granulocyte-colony stimulating factors in the context of treatment,
prophylaxis, peripheral blood stem cell mobilization, or previous investigational
study setting. This also includes exclusion for history of interferon, epoetin, and
intravenous immunoglobulin (IVIG) exposure
7. Receipt of live vaccination, or exposure to communicable viral diseases such as,
varicella, mumps, or measles within the 4 weeks prior to Screening
8. Surgery within the 4 months prior to Screening
9. Use of any prescription medicine (with the exception of contraceptives) within 7 days
or at least 5 half-lives, whichever is longer. Use of oral or parenteral anticoagulant
or antiplatelet agents and corticosteroids should be specifically queried
10. Administration of a drug by depot injection (with exception of depot contraception)
within 30 days prior to Randomization or 5 half-lives of that drug, whichever is
longer
11. Use of over the counter medications, including aspirin and non-steroidal
anti-inflammatory drugs, or natural preparations (dietary supplement or herbal
product) within 7 days or at least 5 half-lives, whichever is longer. Vitamins and
calcium are allowed (not to exceed 100% Daily Value)
12. History of drug or alcohol abuse within 2 years prior to Randomization, as determined
by the investigator or a positive urine screen for drugs of abuse (UDS) at Screening.
Screening for drugs of abuse will minimally include cannabinoids, opiates,
barbiturates, amphetamines, cocaine, benzodiazepines, and alcohol
13. Drug sensitivity, allergic reaction to, or known hypersensitivity/idiosyncratic
reaction to Escherichia coli-derived proteins, filgrastim, other granulocyte-colony
stimulating factors, or pegylated agents
14. History of splenic rupture (or subject who is asplenic), pulmonary infiltrate or
pneumonia, sickle cell disease, chronic neutropenia, thrombocytopenia, or vasculitis
15. Any clinically significant, as determined by the investigator, abnormal laboratory
evaluations, including human immunodeficiency virus antibody (HIVAb), hepatitis B
virus surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), and liver function
including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) the upper limit of normal taken at Screening. Negative HIVAb status will be confirmed
at Screening and the results will be maintained confidentially by the study site
16. Donated or lost 475 mL or more blood volume (including plasmapheresis) or had a
transfusion of any blood product within 3 months prior to Screening
17. Participated in another clinical research study with administration of investigational
drug within 30 days prior to Randomization
18. Potentially not be able to comply with the requirements of this clinical trial, to
communicate effectively with study personnel, or is considered by the Investigator,
for any reason, to be an unsuitable candidate for the study